製品名:2-(6-Chloropyridazin-3-yl)-2-phenylacetonitrile

IUPAC Name:2-(6-chloropyridazin-3-yl)-2-phenylacetonitrile

CAS番号:73535-73-6
分子式:C12H8ClN3
純度:95%
カタログ番号:CM275205
分子量:229.67

包装単位 有効在庫 価格(USD) 数量
CM275205-250mg in stock ŴŴ
CM275205-1g in stock țȁƙ
CM275205-5g in stock ƀȁƻ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:73535-73-6
分子式:C12H8ClN3
融点:-
SMILESコード:N#CC(C1=NN=C(Cl)C=C1)C2=CC=CC=C2
密度:
カタログ番号:CM275205
分子量:229.67
沸点:
MDL番号:
保管方法:

Category Infos

Pyridazines
Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

Column Infos

Neflamapimod
Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.

Related Products